Onterris (ONT) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $178.7M, up 6.4% year-over-year, and record nine-month revenue of $507.4M, driven by organic growth and acquisitions, despite lower emergency response and treatment technology revenues.

• Q3 Consolidated Adjusted EBITDA reached $28.3M (15.8% margin), up 21.5% year-over-year; nine-month Adjusted EBITDA was $68.5M.

• Diluted Adjusted EPS rose to $0.41 in Q3 2024, a 32.3% increase year-over-year; Q3 net loss was $10.6M ($0.39 LPS).

• Six acquisitions completed in 2024, including Spirit, Origins, EPIC, 2DOT, ETA, and Paragon, expanding capabilities and geographic reach.

• Operating cash flow was negative $9.7M for the nine months ended September 30, 2024, mainly due to higher receivables and integration-related delays.

Financial highlights

• Q3 revenue: $178.7M (up 6.4% year-over-year); nine months: $507.4M (up 10.7%).

• Q3 Adjusted EBITDA: $28.3M (15.8% margin); nine months: $68.5M (13.5% margin).

• Q3 Adjusted Net Income: $19.1M ($0.41 Adj EPS); Q3 net loss: $10.6M.

• Cost of revenues as a percentage of revenue decreased to 59.1% in Q3 2024 from 60.8% in Q3 2023.

• Interest expense increased to $4.1M in Q3 2024, reflecting higher rates and debt balances.

Outlook and guidance

• Reaffirmed full-year 2024 guidance: revenue of $690M–$740M and Adjusted EBITDA of $95M–$100M.

• Q4 2024 revenue expected to grow 10–15% year-over-year, with EBITDA margin up 350–400 basis points.

• PFAS-related revenue in labs and consulting projected to grow 30% and 75% respectively in FY24.

• Guidance excludes any benefit from future acquisitions.

• Management expects continued revenue growth, supported by regulatory tailwinds and resilient demand.